Holen Sie sich die Stockscreener-App
149.73
1.55%
-2.35
Vorhandelsmarkt:
150.36
0.63
+0.42%
Novartis Ag Adr Aktie (NVS) Neueste Nachrichten
Generalized Myasthenia Gravis Market on the Brink of Change: 8 Promising Late-Stage Drugs Signal a New Treatment Era | DelveInsight - GlobeNewswire Inc.
Book value per share of Novartis AG ADR Cert Deposito Arg Repr 0.25 ADRs – BCBA:NVSC - TradingView — Track All Markets
Novartis AG stock (CH0012005267): Is its Innovative Medicines focus strong enough to unlock new upsi - AD HOC NEWS
NVS Technical Analysis | Trend, Signals & Chart Patterns | NOVARTIS AG-SPONSORED ADR (NYSE:NVS) - ChartMill
Novartis AG stock: Why Fabhalta momentum matters for investors now - AD HOC NEWS
Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030 - ChartMill
Novartis AG-Sponsored ADR (NYSE:NVS) Presents a Compelling Case for Dividend Investors - ChartMill
NVS Stock Price, Quote & Chart | NOVARTIS AG-SPONSORED ADR (NYSE:NVS) - ChartMill
Novartis AG stock: What investors should know about its steady pharma powerhouse status - AD HOC NEWS
Novartis AG (NVS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Novartis ADR earnings beat by $0.06, revenue fell short of estimates - Investing.com
Novartis AG (ADR) Stock: Resilient Pharma Leader with Strong Fundamentals and Growth Potential for N - AD HOC NEWS
Novartis AG Stock: Resilient Pharma Leader with Strong Fundamentals and Strategic Growth Ahead for I - AD HOC NEWS
Novartis AG Stock Historical Valuations - GuruFocus
Novartis Bolsters Immunology Pipeline With Excellergy Deal - Zacks Investment Research
Dow Jones Top Company Headlines at 11 AM ET: Novartis to Buy Excellergy for Up to $2 Billion | Why ... - 富途牛牛
Novartis to acquire Excellergy, strengthening allergy pipeline with next-generation anti-IgE therapy - Proactive Investors
Novartis AG Stock: Strong Analyst Upgrades and Pipeline Momentum Drive Investor Interest in 2026 - AD HOC NEWS
Excellergy to be acquired by Novartis for up to USD 2 billion to advance potentially first-in-class trifunctional effector cell response inhibitors - ChartMill
Novartis AG (NVS) Bonds - GuruFocus
Novartis AG stock gains 2% on SIX Swiss Exchange amid strong SMI performance and positive pharma sec - AD HOC NEWS
Novartis AG stock surges on Bank of America price target hike amid strong pharma pipeline momentum - AD HOC NEWS
Novartis AG Stock Faces Pressure Amid Multi-Billion Oncology Acquisition and Pipeline Advances - AD HOC NEWS
Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026 - ChartMill
Novartis AG Stock Gains Traction on Analyst Upgrades and Oncology Pipeline Momentum in 2026 - AD HOC NEWS
Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2026 Annual General Meeting - Novartis
Novartis AG stock dips on Swiss Exchange amid $3B breast cancer drug acquisition announcement - AD HOC NEWS
Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline - ChartMill
NVS Stock Quote Price and Forecast - CNN
Novartis AG Stock (ISIN: CH0012005267) Holds Steady Amid Analyst Upgrades and Pipeline Momentum - AD HOC NEWS
Novartis AG Stock (ISIN: CH0012005267) Holds Steady Amid Analyst Upgrade and Portfolio Shifts - ad-hoc-news.de
Novartis AG Stock (ISIN: CH0012005267) Holds Steady Amid Pharma Sector Shifts - AD HOC NEWS
Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa - ChartMill
Novartis AG-Sponsored ADR (NYSE:NVS): A Methodical Pick for Steady Dividend Income - ChartMill
Novartis slides as shares trade ex-dividend for annual payout | NVS Stock News - Quiver Quantitative
2.07%
0.27%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):